A hingeless Fc fusion system for site-specific cleavage by IdeS

Abstract

Fusion of proteins to the Fc region of IgG is widely used to express cellular receptors and other extracellular proteins, but cleavage of the fusion partner is sometimes required for downstream applications. Immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS) is a protease with exquisite specificity for human IgG, and it can also cleave Fc-fusion proteins at a single site in the Nterminal region of the CH2 domain. However, the site of IdeS cleavage results in the disulfide-linked hinge region partitioning with the released protein, complicating downstream usage of the cleaved product. To tailor the Fc fragment for release of partner proteins by IdeS treatment, we investigated the effect of deleting regions of IgG-derived sequence that are upstream of the cleavage site. Elimination of the IgGderived hinge sequence along with several residues of the CH2 domain had negligible effects on expression and purity of the fusion protein, while retaining efficient processing by IdeS. An optimal Fc fragment comprising residues 235-447 of the human IgG1 heavy chain sufficed for efficient production of fusion proteins and minimized the amount of residual Ig-derived sequence on the cleavage product following IdeS treatment. Pairing of this truncated Fc fragment with IdeS cleavage enables highly specific cleavage of Fc-fusion proteins, thus eliminating the need to engineer extraneous cleavage sequences. This system should be helpful for producing Fc-fusion proteins requiring downstream cleavage, particularly those that are sensitive to internal miscleavage if treated with alternative proteases.Abbreviations: EPOR, erythropoietin receptor; Fc, fragment crystallizable; IdeS, Immunoglobulin G-degrading enzyme of Streptococcus pyogenes; mAb, monoclonal antibody; PBS, phosphate-buffered saline; SEC, size exclusion chromatography; scFv, single chain variable fragment; TRAILR2, TNF-related apoptosis inducing ligand receptor 2

Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer

“…However, a truncated Fc with only Leu-Gly-Gly in the hinge region was cloned into the vector. 23 The encoded plasmid was transiently transfected into Expi293 cells (Life technologies) using polyethylenimine (PEI). For 4-1BB, the eluted protein was concentrated, cleaved by IdeS and purified by a Protein A column.…”

Crystal structure of the human 4-1BB/4-1BBL complex

“…A gene encoding the extracellular region of human 4-1BB (residues 24-160) with C121S, N138D, and N149Q mutations was cloned as an N-terminal fusion to a hingeless human IgG1 Fc as previously described (23). 4-1BB and other members of the TNFR superfamily are comprised by cysteine-rich repeats containing large numbers of disulfide bonds.…”

“…The Fc portion of the 4-1BB-Fc molecule was cleaved using IdeS protease in a manner similar to that previously described (23). The purified 4-1BB-Fc was mixed at a 1:15 ratio (IdeS:4-1BB-Fc, w/w) in 10 mM phosphate, pH 7.2, 150 mM NaCl and the mixture was incubated overnight at room temperature with gentle mixing.…”

An antidote approach to reduce risk and broaden utility of antibody-based therapeutics

“…rLC/MS was used to confirm the incorporation of the nnAA and conjugation of antidote candidates. This was performed with an Agilent 1200 series HPLC coupled to an Agilent 6520 accurate mass Q-TOF LC/MS with an electrospray ionization source as previously described ( 41 ). Proteins were first reduced with 50 m m DTT at 37 °C for 15 min at 0.5 μg/ml, and then 2 μg of reduced antibody was loaded onto a Poroshell 300SB-C3 column (2.1 × 75 mm, Agilent catalog no.…”